OpenSAFELY: The impact of COVID‐19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate
British Journal of Clinical Pharmacology · 2025
DOI: 10.1111/bcp.16062 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Andrew D Brown und 27 weiteren Autor:innen. Beteiligte Einrichtung: Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK. Hauptthemen laut MEDLINE: Leflunomide, COVID-19, Antirheumatic Agents, Drug Monitoring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council, Department of Health.
Abstract (Originalsprache)
Aims
The COVID‐19 pandemic created unprecedented pressure on healthcare services. This study investigates whether disease‐modifying antirheumatic drug (DMARD) safety monitoring was affected during the COVID‐19 pandemic.
Methods
A population‐based cohort study was conducted using the OpenSAFELY platform to access electronic health record data from 24.2 million patients registered at general practices using TPP's SystmOne software. Patients were included for further analysis if prescribed azathioprine, leflunomide or methotrexate between November 2019 and July 2022. Outcomes were assessed as monthly trends and variation between various sociodemographic and clinical groups for adherence with standard safety monitoring recommendations.
Results
An acute increase in the rate of missed monitoring occurred across the study population (+12.4 percentage points) when lockdown measures were implemented in March 2020. This increase was more pronounced for some patient groups (70–79 year‐olds: +13.7 percentage points; females: +12.8 percentage points), regions (North West: +17.0 percentage points), medications (leflunomide: +20.7 percentage points) and monitoring tests (blood pressure: +24.5 percentage points). Missed monitoring rates decreased substantially for all groups by July 2022. Consistent differences were observed in overall missed monitoring rates between several groups throughout the study.
Conclusion
DMARD monitoring rates temporarily deteriorated during the COVID‐19 pandemic. Deterioration coincided with the onset of lockdown measures, with monitoring rates recovering rapidly as lockdown measures were eased. Differences observed in monitoring rates between medications, tests, regions and patient groups highlight opportunities to tackle potential inequalities in the provision or uptake of monitoring services. Further research should evaluate the causes of the differences identified between groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bennett Institute for Applied Data Science, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK.
- London School of Hygiene and Tropical Medicine, London, UK.
- Centre for Rheumatic Diseases, King's College London, UK.
- Northumbria University, Newcastle upon Tyne, UK.
- TPP, Leeds, UK.
ORCID-Profile: Andrew D Brown, Victoria Speed, Chris Wood, Andrea L Schaffer
Förderung
- Wellcome Trust
- Medical Research Council
- Department of Health
- National Institute for Health and Care Research
- Health Data Research UK
- UK Research and Innovation
Zitieren
APA
Brown, A. D., Fisher, L., Curtis, H. J., Wiedemann, M., Hulme, W. J., Speed, V., Hopcroft, L. E. M., Cunningham, C., Costello, R. E., Galloway, J. B., Russell, M. D., Bechman, K., Kurt, Z., Croker, R., Wood, C., Walker, A. J., Schaffer, A. L., Bacon, S. C. J., Mehrkar, A., …, & MacKenna, B. (2025). OpenSAFELY: The impact of COVID‐19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16062
Vancouver
Brown AD, Fisher L, Curtis HJ, Wiedemann M, Hulme WJ, Speed V, et al. OpenSAFELY: The impact of COVID‐19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate. British Journal of Clinical Pharmacology. 2025. doi:10.1111/bcp.16062
BibTeX
@article{Brown2025,
author = {Brown, Andrew D and Fisher, Louis and Curtis, Helen J and Wiedemann, Milan and Hulme, William J and Speed, Victoria and Hopcroft, Lisa E M and Cunningham, Christine and Costello, Ruth E and Galloway, James B and Russell, Mark D and Bechman, Katie and Kurt, Zeyneb and Croker, Richard and Wood, Chris and Walker, Alex J and Schaffer, Andrea L and Bacon, Seb C J and Mehrkar, Amir and Hickman, George and Bates, Chris and Cockburn, Jonathan and Parry, John and Hester, Frank and Harper, Sam and Goldacre, Ben and OpenSAFELY Collaborative, OpenSAFELY Collaborative and MacKenna, Brian},
title = {OpenSAFELY: The impact of COVID‐19 on azathioprine, leflunomide and methotrexate monitoring, and factors associated with change in monitoring rate},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1111/bcp.16062}
}
EUVIMED